Cargando…

In-vitro pH-responsive release of imatinib from iron-supplement coated anatase TiO(2) nanoparticles

Targeted drug delivery is one such precision method of delivering medication inside the human body which can vanquish all the limitations of the conventional chemotherapeutic techniques. In the present study, two types of nanoparticles (NPs) were chosen for the in-vitro pH-responsive release study o...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhullar, Shilpy, Goyal, Navdeep, Gupta, Shikha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8931044/
https://www.ncbi.nlm.nih.gov/pubmed/35301335
http://dx.doi.org/10.1038/s41598-022-08090-7
Descripción
Sumario:Targeted drug delivery is one such precision method of delivering medication inside the human body which can vanquish all the limitations of the conventional chemotherapeutic techniques. In the present study, two types of nanoparticles (NPs) were chosen for the in-vitro pH-responsive release study of the drug, Imatinib, namely anatase Titanium Dioxide nanoparticles (TiO(2) NPs) and iron-capped TiO(2) NPs, designated as Fe@TiO(2) NPs. The novelty of this work lies behind the use of commercially available iron supplement ‘Autrin’ meant for human consumption, as the material to coat the TiO(2) NPs to synthesize Fe@TiO(2) NPs. The synthesized NPs were analyzed by XRD, HR‐TEM, SAED, EDX and VSM. UV–Vis spectroscopy was performed for absorption studies. Fe@TiO(2) NPs showed superparamagnetic behavior and thus they are able to ensure the facile transfer of Imatinib via external magnetic fields. The results obtained from in-vitro drug release studies depicted that both TiO(2) NPs and Fe@TiO(2) NPs showed a controlled pH-sensitive delivery of the loaded Imatinib molecules. Moreover, both types of NPs do not result in the formation of ROS under human physiological conditions. These results can lay the foundation to the development of efficacious targeted drug delivery systems in the healthcare sector.